Plain-English translation of NCT06790394 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
Researchers are testing the reliability of a diagnostic imaging agent called florbetaben, which is injected into the bloodstream and then shows up on a special PET scan to reveal amyloid protein deposits in the heart. This study will help doctors determine whether florbetaben PET imaging produces consistent and reproducible results when patients are scanned twice. The goal is to establish whether this imaging method is reliable enough to use routinely for diagnosing cardiac amyloidosis.
Currently, doctors need better ways to reliably detect amyloid buildup in the heart without invasive procedures. If this imaging method produces consistent results, it could become an important diagnostic tool to help patients get accurate diagnoses and start treatment earlier.
You likely qualify if…
You likely don't qualify if…
You will visit the research clinic twice—once for a baseline imaging session and once for a follow-up session. At each visit, you will receive an injection of the imaging agent and then undergo a PET scan of your heart, which takes about 30–60 minutes. The researchers may also collect blood samples to measure how your body metabolizes the imaging agent. Your participation helps determine whether this imaging method gives reliable and consistent results for detecting heart amyloidosis.
AI-generated summary from trial data · Aug 16, 2026 · Not medical advice
United Kingdom